The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Market Size Of The Idiopathic Pulmonary Fibrosis Market Compare Between 2026 And 2030?
The idiopathic pulmonary fibrosis market size has seen significant growth in recent years. It is anticipated to increase from $4.37 billion in 2025 to $4.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. This historical expansion can be attributed to several factors including limited therapeutic choices for fibrotic lung diseases, an increasing elderly population, improved clinical identification of IPF, the approval of nintedanib and pirfenidone, and a rise in hospital-based management of chronic lung conditions.
The idiopathic pulmonary fibrosis market is projected to undergo significant expansion in the coming years. By 2030, its size is expected to reach $6.16 billion, progressing at a compound annual growth rate (CAGR) of 7.2%. This anticipated growth over the forecast period is fueled by several factors, including increasing research investment in pulmonary fibrosis, the development of next-generation antifibrotic drugs, a greater reliance on real-world evidence in making treatment decisions, the expansion of online and specialty pharmacy channels, and a rising awareness of rare respiratory diseases. Prominent trends for the forecast period include the increasing adoption of antifibrotic therapies, a heightened focus on early and accurate diagnosis, a growing use of combination drug therapies, the expansion of home-based and long-term disease management, and increased participation in clinical trials for novel therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Which Key Factors Are Driving The Idiopathic Pulmonary Fibrosis Market Growth?
The idiopathic pulmonary fibrosis market is anticipated to experience growth due to an expanding geriatric population. This demographic segment encompasses elderly individuals or senior citizens within a given society. Aging leads to structural and functional changes in the lungs, increasing the vulnerability of older individuals to respiratory conditions like IPF. This age-related susceptibility contributes to the overall demand for IPF treatments. For instance, in January 2024, the US-based non-profit organization, Population Reference Bureau, reported that the number of Americans aged 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. As a result, this age group’s proportion of the total U.S. population will grow from 17% to 23% during this period. Therefore, the increasing geriatric population is propelling the growth of the idiopathic pulmonary fibrosis market.
What Are The Main Segments Within The Idiopathic Pulmonary Fibrosis Market Segment Structure?
The idiopathic pulmonary fibrosis market covered in this report is segmented –
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users
Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies
Which Trends Are Guiding The Direction Of The Idiopathic Pulmonary Fibrosis Market?
Leading companies active in the idiopathic pulmonary fibrosis (IPF) market are concentrating on advanced products, such as anti-fibrotic small-molecule inhibitors, to maintain their market position. Anti-fibrotic small-molecule inhibitors are a class of pharmaceutical compounds engineered to target and suppress the body’s fibrotic mechanisms. For instance, in June 2023, Insilico Medicine, a US-based clinical-stage biotechnology company utilizing generative artificial intelligence (AI), revealed the start of Phase II clinical trials for INS018_055, which is the world’s inaugural anti-fibrotic small molecule inhibitor designed through generative AI. This achievement signifies the initial dose given to patients in the trial, a randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of a 12-week oral dosage of INS018_055 in individuals with idiopathic pulmonary fibrosis (IPF). This inventive strategy employs AI in the development of new drugs, highlighting a prospective improvement in treating idiopathic pulmonary fibrosis (IPF) diseases.
Who Are The Companies Participating In The Idiopathic Pulmonary Fibrosis Market?
Major companies operating in the idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
Get The Full Idiopathic Pulmonary Fibrosis Market Report:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Which Region Is The Top Contributor To The Idiopathic Pulmonary Fibrosis Market By Share?
North America was the largest region in the idiopathic pulmonary fibrosis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Idiopathic Pulmonary Fibrosis Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Browse Through More Reports Similar to the Global Idiopathic Pulmonary Fibrosis Market 2026, By The Business Research Company
Cystic Fibrosis Cf Therapeutics Market Report 2026
Non Cystic Fibrosis Bronchiectasis Market Report 2026
Interstitial Lung Disease Market Report 2026
https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model